Drug Profile

Tat protein based HIV vaccine - Vaxxit

Alternative Names: TatImmune

Latest Information Update: 31 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Istituto Superiore di Sanita
Developer VAXXIT
Class AIDS vaccines
Mechanism of Action Immunomodulators; Tat gene product inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II HIV infections

Most Recent Events

29 Aug 2019 Tat protein based HIV vaccine is still in phase II trials for HIV infections (Treatment-experienced) in Italy and South Africa (VAXXIT website, August 2019)
10 May 2016 VAXXIT has patent protection for the Tat-based HIV vaccine worldwide
09 May 2016 Phase-II clinical trials in HIV infections (Treatment-experienced) in Italy (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com